The neutropenia caused by tumor chemotherapy can easily lead to potentially life-threatening complications. The Rolontis product treatment plan can effectively prevent and treat chemotherapy-induced neutropenia, helping cancer patients with treatment and recovery. Sinopharm International adheres to the functional mission of serving the national strategy and promoting people's health and well-being. It leverages the role of Sinopharm Group's international business strategy platform for pharmaceutical and health, introduces Rolontis products from South Korea, improves the safety and effectiveness of cancer patient treatment, and promotes the optimization and upgrading of the pharmaceutical and health supply chain industry chain.On October 24th, China Pharmaceutical Foreign Trade Co., Ltd., a subsidiary of Sinopharm International, and Hanmei Pharmaceutical Co., Ltd. signed a Rolontis product cooperation agreement, marking a new chapter of cooperation in the field of biomedicine based on pharmacy equipment cooperation between the two parties. Zhou Song, Secretary of the Party Committee and Chairman of Sinopharm International, had in-depth exchanges with Park Jae hyun, CEO of Hanmei Pharmaceuticals, hoping that both sides can carry out multidimensional cooperation in product research and development, technology introduction, and cooperative production. Park Jae hyun expressed deep admiration for the values and business layout of Sinopharm International, and expressed willingness to leverage their respective advantages to innovate cooperation models, launch more achievements, and continuously enhance the competitiveness of both sides in the global pharmaceutical and health industry chain.

Shen Haikun, Executive Director of Overseas Sales Department of Hanmei Pharmaceutical, Li Jiongyou, Director and Senior Director of Hanmei Pharmaceutical Research in Beijing, Zhang Haoji, Deputy General Manager of Sinopharm International, Miao Lingjiong, Deputy General Manager of Sinopharm Foreign Trade, and others attended.
Reprinted from Sinopharm International